RWA Civil Services
Current Affairs - Daily 20 November 2026

How Often Did CancerSpot Detect Cancer Signals?

CancerSpot-Detecting Signals of Multiple Cancers with a Single Blood Test

Why in News?

  • A study involving 1,480 participants across 43 hospitals in India evaluated CancerSpot, a blood test designed to detect signals of multiple cancers. Participants included patients with 14 types of cancer at different stages, none of whom had begun treatment. Healthy volunteers and people with benign growths were included for comparison.
  • The test showed an overall sensitivity of 72% and a false-positive rate of 1.4%. The first figure indicates how often the test detected a signal in people with cancer. The second indicates how often it incorrectly flagged a signal in people without cancer.

How Does CancerSpot Work?

  • Developed by Bengaluru-based Strand Life Sciences, CancerSpot analyses cell-free DNA (cfDNA) in plasma, the liquid component of blood. Cell-free DNA consists of small DNA fragments released by cells into the bloodstream.
  • The test examines DNA methylation, a process in which chemical tags attach to DNA without altering the sequence of its genetic letters. Certain methylation patterns can change in cancer. CancerSpot uses DNA sequencing and computational analysis to identify cancer-associated patterns.
  • The study found that higher concentrations of cell-free DNA in the blood were associated with a higher proportion of fragments carrying cancer-associated methylation marks. This helps explain why the cancer signal was stronger in some blood samples.

What Do the Figures Mean?

  • 72% sensitivity - Under conditions similar to those of the study, the test would be expected to detect a signal in about 72 out of every 100 people with cancer and miss about 28. This figure covers all cancer types and stages studied. Detection rates for a particular cancer or for stage I cancers alone may differ.
  • 1.4% false-positive rate - Among 1,000 people without cancer, about 14 would be expected to receive a positive result. This corresponds to a specificity of 98.6%. The probability that a person with a positive result actually has cancer also depends on how common cancer is in the population being tested.

Significance and Limitations

  • A single blood test that can detect signals of several cancers could be particularly useful for cancers for which routine screening is unavailable. A positive result requires further investigation through clinical assessment, imaging and, where appropriate, a tissue biopsy to confirm the diagnosis.
  • This was a case-control study. It compared people already diagnosed with cancer with participants who did not have cancer. Long-term studies are needed to establish how many cancers routine screening would detect early in people without symptoms and whether it would reduce cancer deaths.
  • A negative result can miss cancer. People should therefore continue routine cancer screening recommended for their age and risk profile.

Practice Question

What does the 1.4% false-positive rate reported in the CancerSpot study mean?

(A) Among 1,000 people with cancer, the test may miss about 14 cases.
 (B) Among 1,000 people who test positive, only about 14 actually have cancer.
 (C) Among 1,000 people without cancer, the test may detect a cancer signal in about 14.
 (D) Among every 1,000 people tested, about 14 will develop cancer in the future.

Answer - (C)

Explanation - The false-positive rate is calculated among people without cancer. At 1.4%, about 14 out of 1,000 people in this group would be expected to receive a positive result. Sensitivity is calculated among people who have cancer and measures the proportion the test correctly identifies.